GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mallinckrodt PLC (OTCPK:MCKPF) » Definitions » Asset Turnover

Mallinckrodt (Mallinckrodt) Asset Turnover : 0.10 (As of Sep. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Mallinckrodt Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Mallinckrodt's Revenue for the three months ended in Sep. 2023 was $497 Mil. Mallinckrodt's Total Assets for the quarter that ended in Sep. 2023 was $4,951 Mil. Therefore, Mallinckrodt's Asset Turnover for the quarter that ended in Sep. 2023 was 0.10.

Asset Turnover is linked to ROE % through Du Pont Formula. Mallinckrodt's annualized ROE % for the quarter that ended in Sep. 2023 was 2,919.06%. It is also linked to ROA % through Du Pont Formula. Mallinckrodt's annualized ROA % for the quarter that ended in Sep. 2023 was -139.35%.


Mallinckrodt Asset Turnover Historical Data

The historical data trend for Mallinckrodt's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mallinckrodt Asset Turnover Chart

Mallinckrodt Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.25 0.30 0.22 0.24 -

Mallinckrodt Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.08 0.07 0.09 0.10

Competitive Comparison of Mallinckrodt's Asset Turnover

For the Drug Manufacturers - Specialty & Generic subindustry, Mallinckrodt's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mallinckrodt's Asset Turnover Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mallinckrodt's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Mallinckrodt's Asset Turnover falls into.



Mallinckrodt Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Mallinckrodt's Asset Turnover for the fiscal year that ended in Dec. 2022 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2022 )/( (Total Assets (A: Dec. 2021 )+Total Assets (A: Dec. 2022 ))/ count )
=0/( (8916.3+6013.8)/ 2 )
=0/7465.05
=0.00

Mallinckrodt's Asset Turnover for the quarter that ended in Sep. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Sep. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Sep. 2023 ))/ count )
=497/( (5106.9+4794.8)/ 2 )
=497/4950.85
=0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Mallinckrodt  (OTCPK:MCKPF) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Mallinckrodt's annulized ROE % for the quarter that ended in Sep. 2023 is

ROE %**(Q: Sep. 2023 )
=Net Income/Total Stockholders Equity
=-6899.2/-236.35
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-6899.2 / 1988)*(1988 / 4950.85)*(4950.85/ -236.35)
=Net Margin %*Asset Turnover*Equity Multiplier
=-347.04 %*0.4015*-20.9471
=ROA %*Equity Multiplier
=-139.35 %*-20.9471
=2,919.06 %

Note: The Net Income data used here is four times the quarterly (Sep. 2023) net income data. The Revenue data used here is four times the quarterly (Sep. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Mallinckrodt's annulized ROA % for the quarter that ended in Sep. 2023 is

ROA %(Q: Sep. 2023 )
=Net Income/Total Assets
=-6899.2/4950.85
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-6899.2 / 1988)*(1988 / 4950.85)
=Net Margin %*Asset Turnover
=-347.04 %*0.4015
=-139.35 %

Note: The Net Income data used here is four times the quarterly (Sep. 2023) net income data. The Revenue data used here is four times the quarterly (Sep. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Mallinckrodt Asset Turnover Related Terms

Thank you for viewing the detailed overview of Mallinckrodt's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Mallinckrodt (Mallinckrodt) Business Description

Traded in Other Exchanges
N/A
Address
College Business and Technology Park, Cruiserath, Blanchardstown, Dublin, IRL, 15
Mallinckrodt PLC develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies. Its areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company operates its business in two reportable segments namely Specialty Brands which include specialty pharmaceutical brands; and Specialty Generics which includes niche specialty generic drugs and active pharmaceutical ingredients. It generates maximum revenue from the Specialty Brands segment. Geographically, it derives a majority of its revenue from the United States.
Executives
Alta Fundamental Advisers Llc 10 percent owner 1500 BROADWAY, SUITE 704, NEW YORK NY 10036
Jason Daniel Goodson officer: EVP & Head of Corp Development 106 CENTRAL PARK AVENUE, WENTZVILLE MO 63885
James R Sulat director
Paul Bisaro director
Sigurdur O Olafsson director, officer: President and CEO 360 MOUNT KEMBLE AVENUE, MORRISTOWN NJ 07960
Stephen Andrew Welch officer: EVP & Head of Spec Generics 18440 BRIDGEMORE LANE, LOUISVILLE KY 40245
Peter C Richardson officer: EVP & Chief Scientific Officer 28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Susan Michele Silbermann director C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540
Lisa French officer: EVP & Chief Commercial Officer 301 CONTINENTAL LANE, PAOLI PA 19301
Mark Anthony Tyndall officer: EVP & Chief Legal Offi & Secre 1101 Q ST NW, WASHINGTON DC 20009
Henriette Nielsen officer: EVP & Chief Transformation OFC 202 WEST 85TH STREET, APT. 5, NEW YORK NY 10024
Karen Ling director C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Anne Clem Whitaker director 109 BRIERY BRANCH COURT, MORRISVILLE NC 27560
Olifant Luxco S.a R.l. 10 percent owner 19, RUE DE BITBOURG, LUXEMBOURG N4 L-1273
Paul Rutherford Carter director SOUTH BUILDING, 2 ROUNDWOOD AVENUE, STOCKLEY PARK X0 UB11 1AF

Mallinckrodt (Mallinckrodt) Headlines

From GuruFocus